Market Place
Sourcing Support
Koselugo Shows Improve in NF1 Plexiform Neurofibromas in Ph 3 Trial
12 Nov 2024 //
BUSINESSWIRE
China NMPA approves Koselugo for paediatric patients
08 May 2023 //
PHARMABIZ
Koselugo approved in Japan for paediatric patients with plexiform neurofibromas
28 Sep 2022 //
PHARMABIZ
AstraZeneca Pharma India gets nod to import, market Selumetinib capsules
26 Sep 2021 //
BUSINESS-STANDARD
AstraZeneca Pharma India gets nod to import, market Selumetinib capsules
25 Sep 2021 //
BUSINESS-STANDARD
Selumetinib recommended for approval in the EU by CHMP as the first medicine
26 Apr 2021 //
PRESS RELEASE
Selumetinib granted orphan drug designation in Japan neurofibromatosis type 1
30 Jun 2020 //
PRESS RELEASE
KOSELUGO™ Approved In US For Pediatric Patients With Neurofibromatosis Type 1
14 Apr 2020 //
BUSINESSWIRE
AstraZeneca Wins First FDA Drug Nod for NF1
11 Apr 2020 //
FDA
AstraZeneca and MSD announces US FDA accepts selumetinib NDA
15 Nov 2019 //
PHARMABIZ
US FDA accepts regulatory submission for selumetinib in neurofibromatosis type 1
15 Nov 2019 //
PRESS RELEASE
AZ, Merck win red carpet treatment at the FDA as a 3-time loser seeks speedy OK
15 Nov 2019 //
ENDPTS
AZ`s struggling cancer drug nabs priority review in rare disease
15 Nov 2019 //
FIERCE PHARMA
Arcus hires ex-AbbVie, Genentech researcher as CMO
02 May 2019 //
FIERCE BIOTECH
Selumetinib Granted US Breakthrough Therapy Desig in Neurofibromatosis Type 1
01 Apr 2019 //
BUSINESSWIRE
Second chance for AstraZeneca’s selumetinib with breakthrough designation
01 Apr 2019 //
PMLIVE
Orphan Drug Regulations in Europe
27 Aug 2018 //
RAPS
AZ and MSD get orphan designation for neurofibromatosis drug
03 Aug 2018 //
PHARMA TIMES
AZ cancer trial, GSK attempts R&D turnaround, Sanofi digital investment & more
26 Jul 2018 //
FIERCE BIOTECH
AstraZeneca’s Cancer Drugs Mostly Soar With One Bomb Amidst Quarterly Report
26 Jul 2018 //
BIOSPACE
Selumetinib continues to cause headaches as AstraZeneca dumps a failed PhIII
26 Jul 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.